Published On : 24 March 2025
• The global Pharmacogenomics (PGx) market is projected to grow from US$ 8,569.5 million in 2024 to US$ 14,590 million by 2030, reflecting a CAGR of 9.3% during the forecast period.
Email: help@intelmarketresearch.com +91 9169164321
• Pharmacogenomics (PGx) is a branch of precision medicine that studies how an individual’s genetic makeup affects their response to drugs. It combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to tailor drug treatments for individual patients, improving efficacy and reducing adverse effects. By analyzing genetic variations, pharmacogenomics helps in developing personalized treatment plans, minimizing trial-and-error prescriptions, and optimizing drug dosages.
• The rising adoption of precision medicine, technological advancements in genomic research, and the increasing prevalence of chronic diseases are driving market expansion. In 2023, North America accounted for the largest market share due to well-established healthcare infrastructure and robust investment in genomics research.
Email:
•Polymerase Chain Reaction (PCR) – Widely used for detecting genetic mutations.
•Microarray – Enables large-scale genetic analysis.
•Sequencing – Next-generation sequencing (NGS) drives advancements in PGx.
•Other – Includes electrophoresis and mass spectrometry techniques.
• Cardiovascular Diseases (CVD) – PGx helps in optimizing drug efficacy for heart-related conditions.
• Central Nervous System (CNS) Disorders – Used for psychiatric and neurological diseases.
• Cancer/Oncology – Key area of PGx application in targeted therapies.
• Infectious Diseases – Enhancing drug response in viral and bacterial infections.
Email: help@intelmarketresearch.com +91 9169164321
